Welcome to BioSeeker Group!

Cancer Antibodies: Drug Target Atlas and Competitive Outlook

Additional Information

Published Date Nov 1, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 2361
PDF Fact Sheet View Fact Sheet for the report Cancer Antibodies: Drug Target Atlas and Competitive Outlook in PDF
Format PDF
Publisher BioSeeker Group
Product Line View All Available Cancer Highlights Reports

Availability: In stock

Regular Price: $2,450.00

Special Price: $1,225.00

Quick Overview

This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Antibodies: Drug Target Atlas and Competitive Outlook.

    To find out more about Cancer Antibodies: Drug Target Atlas and Competitive Outlook, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Antibodies: Drug Target Atlas and Competitive Outlook is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Personalized medicine is very much about fitting target profiles of drugs towards disease mechanism(s). This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis which allows you to discover:

* Where the competition is; Which targets, tumor types and companies are setting the path?

* How much R&D effort has gone towards different targets and what is known about the target?

* Indication expansion opportunities

* Drug repositioning opportunities

* Which pathways are targeted, by what and how?

* What is truly new and unique in the antibody pipeline in cancer?

* How new and unique your target strategy really is

* Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

BioSeeker builds its analysis on a comprehensive base of 572 antibody drugs in cancer from within the portfolio of 205 companies world-wide, from Ceased to Marketed. We have identified 270 drug targets, which we have organized into 279 drug target strategies, and assessed them by four levels:

1. Individual Target: Shows you how individual targets tie into different target strategies and their subsequent R&D progress.

2. Developmental Stage: Shows you the progress and maturation of different target strategies. Identifies which target strategies are new and unique from one developmental stage to the next.

3. Indication: Shows the distribution and deployment of target strategies by cancer indications. The competitive level in each cancer indication is assessed.

4. Company: Provides a cross-examination of each company’s entire pipeline on the basis of its defined drug target strategies, including a Competitive Fall-Out analysis and a corporate pipeline ranking based on 15 parameters.

Our Analysis includes:

* Head-to-head target competing analysis

* Significant drug target overlap analysis

* Cross-sectional R&D profiling of individual drug targets.

* Cross-over analysis of target strategies among different tumor types.

* Competitive Fall-Out analysis of the entire company pipeline: Answering three core questions about each company’s pipeline:
-Where are we?
-Where is our general and specific competition?
-What is the level of competition where we want to be?

* 15 parameter deep corporate pipeline ranking, including both internal and external pipeline factors.

The report serves as an external commercial advocate for your company’s interest in the antibody pipeline in cancer by:

* Better identifying benchmarking peers

* Providing rationale for in/out licensing decisions of drug candidates

* Performing proper drug due diligence

* Strategies for commercial planning

* Guiding Research & Development efforts

1 Executive Summary 3
2 About Cancer Highlights™ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 23
4.2 List of Tables 23
5 Introduction 35
5.1 The Scope of this Report 35
5.2 Definitions 38
5.3 Abbreviations 38
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment 39
6.1 Drug Repositioning in Oncology 39
6.2 Introduction to Targets of Antibody Drugs in Cancer 40
6.2.1 Antigen Binding Targets 49
6.2.2 ATPase Activity Targets 51
6.2.3 Auxiliary Transport Protein Activity Targets 53
6.2.4 B Cell Receptor Activity Targets 56
6.2.5 Binding Targets 57
6.2.6 Carboxypeptidase Activity Targets 58
6.2.7 Catalytic Activity Targets 60
6.2.8 Cell Adhesion Molecule Activity Targets 64
6.2.9 Chaperone Activity Targets 88
6.2.10 Chemokine Activity Targets 91
6.2.11 Cofactor Binding Targets 95
6.2.12 Complement Activity Targets 97
6.2.13 Cysteine-type Peptidase Activity Targets 101
6.2.14 Cytokine Activity Targets 103
6.2.15 Defense/Immunity Protein Activity Targets 110
6.2.16 DNA Topoisomerase Activity Targets 111
6.2.17 Extracellular Ligand-gated Ion Channel Activity Targets 114
6.2.18 Extracellular Matrix Structural Constituent Targets 115
6.2.19 G-protein Coupled Receptor Activity Targets 121
6.2.20 Growth Factor Activity Targets 134
6.2.21 Guanylate Cyclase Activity Targets 149
6.2.22 Hormone Activity Targets 150
6.2.23 Hydrolase Activity Targets 151
6.2.24 Intracellular Ligand-gated Ion Channel Activity Targets 153
6.2.25 Kinase Binding Targets 154
6.2.26 Metallopeptidase Activity Targets 155
6.2.27 MHC Class I Receptor Activity Targets 159
6.2.28 Molecular Function Unknown Targets 160
6.2.29 Oxidoreductase Activity Targets 189
6.2.30 Peptidase Activity Targets 190
6.2.31 Peptide Hormone Targets 192
6.2.32 Protease Inhibitor Activity Targets 194
6.2.33 Protein Binding Targets 196
6.2.34 Protein Serine/Threonine Kinase Activity Targets 197
6.2.35 Receptor Activity Targets 201
6.2.36 Receptor Binding Targets 269
6.2.37 Receptor Signaling Complex Scaffold Activity Targets 282
6.2.38 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 284
6.2.39 Receptor Signaling Protein Tyrosine Phosphatase Activity Targets 286
6.2.40 RNA-directed DNA Polymerase Activity Targets 287
6.2.41 Serine-type Peptidase Activity Targets 288
6.2.42 Structural Constituent of Cytoskeleton Targets 291
6.2.43 Structural Molecule Activity Targets 293
6.2.44 T Cell Receptor Activity Targets 294
6.2.45 Transcription Factor Activity Targets 296
6.2.46 Transcription Regulator Activity Targets 301
6.2.47 Translation Regulator Activity Targets 304
6.2.48 Transmembrane Receptor Activity Targets 305
6.2.49 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 314
6.2.50 Transporter Activity Targets 348
6.2.51 Other Targets 352
6.3 Mutation Profiles of Antibody Drug Targets in Oncology 356
6.3.1 Targets of Antibody Drugs in Cancer Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 356
6.4 Antibody Therapeutics is Stimulated by Available Structure Data on Targets 364
6.5 Target-Target Interactions among Identified Targets of Antibody Drugs in Cancer 368
6.6 Protein Expression Levels of Identified Targets of Antibody Drugs in Cancer 372
6.7 The Drug-Target Competitive Landscape 375
6.8 Pathway Assessment of Antibody Drugs in Cancer 381
6.8.1 Tools for Analysis of Cancer Pathways 382
6.8.2 Pathway Assessment 383
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development 423
7.1 Pre-registrered and Marketed: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 426
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 428
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 430
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 435
7.5 Preclinical Development: New and Unique Drug Target Strategies of Antibody Drugs in Cancer 442
7.6 Drug Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 451
7.7 Target Strategy Development Profiles of Antibody Drugs in Cancer 456
7.7.1 Marketed 462
7.7.2 Phase III 483
7.7.3 Phase II 498
7.7.4 Phase I 568
7.7.5 Preclinical 616
7.7.6 Suspended 696
7.7.7 Ceased 697
7.8 The Competition Through Close Mechanistic Approximation of Antibody Drugs in Cancer 768
8 Selecting Indication for Antibody Drugs in Oncology 777
8.1 Acute Lymphocytic Leukemia 780
8.2 Acute Myelogenous Leukemia 782
8.3 B-cell Lymphoma 784
8.4 Basal Cell Cancer 786
8.5 Biliary Cancer 787
8.6 Bladder Cancer 788
8.7 Bone Cancer 790
8.8 Brain Cancer 793
8.9 Breast Cancer 795
8.10 Cancer (general) 799
8.11 Carcinoid Tumors 800
8.12 Cervical Cancer 801
8.13 Chronic Lymphocytic Leukemia 803
8.14 Chronic Myelogenous Leukemia 806
8.15 Chronic Myelomonocytic Leukemia 807
8.16 CNS Cancer 808
8.17 Colorectal Cancer 809
8.18 Endometrial Cancer 813
8.19 Esophageal Cancer 814
8.20 Ewing’s Sarcoma 815
8.21 Fallopian Tube Cancer 816
8.22 Gastrointestinal Cancer (general) 817
8.23 Gastrointestinal Stomach Cancer 819
8.24 Gastrointestinal Stromal Cancer 821
8.25 Genitourinary Cancer 822
8.26 Glioma 823
8.27 Hairy Cell Leukemia 824
8.28 Head and Neck Cancer 825
8.29 Hematological Cancer (general) 827
8.30 Hodgkin’s Lymphoma 828
8.31 Leiomyo Sarcoma 830
8.32 Leukemia (general) 831
8.33 Liver Cancer 833
8.34 Lung Cancer (general) 835
8.35 Lymphoma (general) 837
8.36 Malignant ascites 838
8.37 Melanoma 839
8.38 Merkel Cell Carcinoma 842
8.39 Mesothelioma 843
8.40 Myelodysplastic Syndrome 844
8.41 Myeloma 846
8.42 Nasopharyngeal Cancer 849
8.43 Neuroblastoma 850
8.44 Neuroectodermal Sarcoma 851
8.45 Neuroendocrine Cancer (general) 852
8.46 non-Hodgkin’s Lymphoma 853
8.47 Non-Small Cell Lung Cancer 857
8.48 Oesophageal Cancer 860
8.49 Oral Cancer 863
8.50 Osteo Sarcoma 864
8.51 Ovarian Cancer 865
8.52 Pancreatic Cancer 868
8.53 Peritoneal Cancer 871
8.54 Pituitary Adenoma 873
8.55 Prostate Cancer 874
8.56 Renal Cancer 877
8.57 Rhabdomyo Sarcoma 879
8.58 Sarcoma (general) 880
8.59 Skin Appendage Cancer 881
8.60 Skin Cancer (general) 882
8.61 Small Cell Lung Cancer 883
8.62 Soft Tissue Sarcoma 885
8.63 Solid Tumor 886
8.64 Squamous Cell Cancer 890
8.65 Synovial Sarcoma 892
8.66 T-cell Lymphoma 893
8.67 Testicular Cancer 894
8.68 Thymoma Cancer 895
8.69 Thyroid Cancer 896
8.70 Unspecified Cancer Type 898
8.71 Vaccine adjunct 905
8.72 Waldenstrom’s hypergammaglobulinemia 906
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator 908
9.1 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change 913
9.2 Company Facts and Ranking 915
9.3 Competitive Fall-Out Assessment 922
9.4 A&G Pharmaceutical 925
9.5 Abbott 929
9.6 Abcam 938
9.7 Abiogen 946
9.8 Ablynx 955
9.9 AC Immune 960
9.10 Acceleron Pharma 964
9.11 Access 968
9.12 Actinium Pharmaceuticals 974
9.13 Active Biotech 980
9.14 Adherex 984
9.15 Affibody 988
9.16 Affimed Therapeutics 995
9.17 Affitech 1006
9.18 AGY Therapeutics 1013
9.19 Aida Pharmaceuticals 1017
9.20 Alder Biopharmaceuticals 1023
9.21 Alethia Biotherapeutics 1030
9.22 Alexion 1034
9.23 Algeta 1038
9.24 ALSP 1046
9.25 Altor BioScience 1053
9.26 Amgen 1057
9.27 Amorfix Life Sciences 1086
9.28 Antisoma 1091
9.29 Aphios 1097
9.30 Apricus Biosciences 1103
9.31 Arana Therapeutics 1111
9.32 Arca biopharma 1115
9.33 Areva 1119
9.34 arGEN-X 1126
9.35 Astellas 1131
9.36 1AstraZeneca 1135
9.37 AVEO 1156
9.38 Bayer 1167
9.39 Berkeley Lab 1173
9.40 Biocon 1177
9.41 Biogen Idec 1181
9.42 BioInvent 1195
9.43 Biolex 1199
9.44 BioLineRx 1206
9.45 Biosceptre 1210
9.46 Biotecnol 1214
9.47 Biotest 1222
9.48 Boehringer Ingelheim 1226
9.49 Bristol-Myers Squibb 1230
9.50 BTG 1253
9.51 Cancer Innovations 1258
9.52 Cancer Research Technology 1263
9.53 Celldex Therapeutics 1280
9.54 Celltrion 1287
9.55 Celtic Pharma 1297
9.56 Center of Molecular Immunology 1302
9.57 Centrose 1310
9.58 CG Therapeutics 1316
9.59 Circadian Technologies 1320
9.60 CSL 1325
9.61 CuraGen 1329
9.62 CureTech 1333
9.63 Customized Therapeutics 1339
9.64 CytImmune Sciences 1347
9.65 Daiichi Sankyo 1351
9.66 Dendreon 1358
9.67 DiaMedica 1363
9.68 Dompe 1367
9.69 Dr Reddy’s 1372
9.70 Dyax 1379
9.71 Eisai 1386
9.72 Elan 1393
9.73 Eli Lilly 1397
9.74 Emergent BioSolutions 1424
9.75 Ergon Pharmaceuticals 1428
9.76 EUSA Pharma 1432
9.77 Expression Drug Designs 1437
9.78 Fabrus 1441
9.79 Faron Pharmaceuticals 1456
9.80 Favrille 1460
9.81 Femta Pharmaceuticals 1467
9.82 FibroGen 1472
9.83 Five Prime Therapeutics 1476
9.84 Fusion Antibodies 1480
9.85 Galaxy Biotech 1484
9.86 GammaCan 1488
9.87 Ganymed Pharmaceuticals 1494
9.88 Gene Techno Science 1498
9.89 Genencor 1502
9.90 Genentech 1507
9.91 Genmab 1517
9.92 Genomic Systems 1538
9.93 GenPat77 1542
9.94 Gilead Sciences 1546
9.95 GlaxoSmithKline 1550
9.96 Gliknik 1558
9.97 Glycotope 1568
9.98 Green Cross 1578
9.99 Hawthorn Pharmaceuticals 1585
9.100 Hoffmann-La Roche 1589
9.101 Human Genome Sciences 1629
9.102 IDM Pharma 1637
9.103 ImClone Systems 1646
9.104 IMED 1653
9.105 Immune Pharmaceuticals 1657
9.106 ImmunoCellular Therapeutics 1661
9.107 ImmunoGen 1665
9.108 Immunomedics 1680
9.109 Immutep 1707
9.110 Innate Pharma 1711
9.111 InNexus Biotechnology 1717
9.112 Intracel 1731
9.113 ISA Pharmaceuticals 1738
9.114 ISU ABXIS 1743
9.115 Johnson & Johnson 1750
9.116 Kaketsuken 1758
9.117 KaloBios 1762
9.118 Kirin Pharma 1766
9.119 Kissei 1773
9.120 Kyowa Hakko Kirin 1780
9.121 Kyto Biopharma 1787
9.122 LFB Biotechnologies 1791
9.123 LG Life Sciences 1805
9.124 MacroGenics 1812
9.125 MAT Biopharma 1820
9.126 Medarex 1827
9.127 MediGene 1834
9.128 MedImmune 1841
9.129 Menarini 1846
9.130 Merck & Co 1851
9.131 Merck KGaA 1857
9.132 Merrimack 1870
9.133 Micromet 1876
9.134 Mitsubishi Tanabe Pharma 1881
9.135 Mycenax 1885
9.136 Neovacs 1889
9.137 Neuren 1895
9.138 NIH 1899
9.139 NKT Therapeutics 1905
9.140 Non-industrial Sources 1909
9.141 Northwest Biotherapeutics 1917
9.142 Novartis 1922
9.143 OncoMed 1936
9.144 OncoTherapy Science 1942
9.145 Oncothyreon 1946
9.146 Onyvax 1951
9.147 Oxford BioMedica 1956
9.148 Paladin Labs 1961
9.149 Panacea 1968
9.150 PanGenetics 1974
9.151 Patrys 1979
9.152 Pepscan Therapeutics 1986
9.153 Peregrine Pharmaceuticals 1991
9.154 Perseus Proteomics 1998
9.155 Pfizer 2003
9.156 PharmAbcine 2022
9.157 Philogen 2045
9.158 Pierre Fabre 2051
9.159 Prima Biomed 2060
9.160 PROBIOMED 2065
9.161 ProCell Therapeutics 2072
9.162 Prochon Biotech 2076
9.163 Progenics Pharmaceuticals 2082
9.164 Ramot 2087
9.165 Recepta biopharma 2091
9.166 Receptor BioLogix 2095
9.167 Regeneron 2101
9.168 Sanofi 2110
9.169 SBI Biotech 2116
9.170 Scancell 2121
9.171 Seattle Genetics 2125
9.172 Shanghai CP Guojian 2136
9.173 Shenogen 2146
9.174 Stainwei Biotech 2150
9.175 Sunol Molecular 2156
9.176 SuppreMol 2161
9.177 Switch Pharma 2166
9.178 Symphogen 2170
9.179 Synageva BioPharma 2178
9.180 SynerGene Therapeutics 2188
9.181 Tactic Pharma 2192
9.182 Takeda 2196
9.183 Tamir Biotechnology 2202
9.184 Targa Therapeutics 2207
9.185 TeGenero 2215
9.186 Teva 2219
9.187 ThromboGenics 2226
9.188 Titan Pharmaceuticals 2231
9.189 Tolerx 2237
9.190 Tracon Pharmaceuticals 2242
9.191 Transgene 2247
9.192 Trillium Therapeutics 2252
9.193 Trion Pharma 2256
9.194 UCB 2264
9.195 United Therapeutics 2270
9.196 Vaccinex 2274
9.197 VasGene Therapeutics 2283
9.198 Viragen 2287
9.199 Viventia Biotech 2293
9.200 Wakunaga 2297
9.201 Wilex 2303
9.202 XBiotech 2307
9.203 Xencor 2312
9.204 Xerion 2331
9.205 Xoma 2337
9.206 Y’s Therapeutics 2343
9.207 YM BioSciences 2347
9.208 Zenotech 2354
10 Disclaimer 2361

1.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Antibody Drugs in Cancer 371
Figure 2: The Drug-Target Competitive Landscape of Antibody Drugs in Cancer - Large Cluster 376
Figure 3: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 1(2) 377
Figure 4: The Drug-Target Competitive Landscape Antibody Drugs in Cancer - Smaller Clusters 2(2) 378
Figure 5: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 1 (2) 379
Figure 6: Head-to-Head Targeting Competitive Landscape of Antibody Drugs in Cancer - 2 (2) 380
Figure 7: Number of Companies per Ranking Level 917

1.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Antibody Drug Pipeline in Oncology by Stage of Development 35
Table 3: Head to Head Target Competition among Antibody Drugs 35
Table 4: Overview of Drug Target Strategy Themes 40
Table 5: Ceased Targets of Antibody Drugs in Cancer 41
Table 6: Official Gene Symbol to Target Profle 43
Table 7: Mutation Frequencies of Antibody Drug Targets 357
Table 8: Identity of Drug Targets with Available Biological Structures 364
Table 9: Number of Target-Target Interactions among Targets of Antibody Drugs in Cancer 369
Table 10: Available Protein Expression Profiles of Antibody Drug Targets 372
Table 11: Pathway Summary 383
Table 12: Drug Targets without any Identified Assigned Pathways 383
Table 13: Pathway Profiles According to BioCarta of Antibody Drug Targets in Oncology 386
Table 14: Pathway Profiles According to KEGG of Antibody Drug Targets in Oncology 400
Table 15: Pathway Profiles According to NetPath of Antibody Drug Targets in Oncology 418
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 423
Table 17: Top Competitive Target Strategies of Antibody Drugs in Cancer 424
Table 18: New and Unique Target Strategies of Antibody Drugs in Cancer in Pre-registration or on the Marketed 426
Table 19: The Competition Through Close Mechanistic Approximation Between Antibody Drugs in Cancer Being Marketed 427
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Antibody Drugs in Cancer 428
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Antibody Drugs in Cancer 429
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Antibody Drugs in Cancer 430
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Antibody Drugs in Cancer 433
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Antibody Drugs in Cancer 435
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Antibody Drugs in Cancer 439
Table 26: New and Unique Target Strategies in Preclinical Development of Antibody Drugs in Cancer 442
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Antibody Drugs in Cancer 447
Table 28: Target Strategies of Suspended or Terminated Antibody Drugs in Cancer 451
Table 29: Connecting Target Strategy with Its Profile Identification Number 456
Table 30: The Competition Through Close Mechanistic Approximation Among Antibody Drugs in Cancer 768
Table 31 Competitive Summary by Cancer Indication of Antibody Drugs 778
Table 32: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Lymphocytic Leukemia 780
Table 33: The Competition through Close Mechanistic Approximation between Acute Lymphocytic Leukemia Drugs 781
Table 34: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Acute Myelogenous Leukemia 782
Table 35: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 783
Table 36: Target Strategy Development Profiles of Antibody Drugs for the Treatment of B-cell Lymphoma 784
Table 37: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs 785
Table 38: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Basal Cell Cancer 786
Table 39: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Biliary Cancer 787
Table 40: The Competition through Close Mechanistic Approximation between Biliary Cancer Drugs 787
Table 41: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bladder Cancer 788
Table 42: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 788
Table 43: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Bone Cancer 790
Table 44: The Competition through Close Mechanistic Approximation between Bone Cancer Drugs 792
Table 45: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Brain Cancer 793
Table 46: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 794
Table 47: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Breast Cancer 795
Table 48: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 797
Table 49: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cancer (general) 799
Table 50: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Carcinoid Tumors 800
Table 51: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Cervical Cancer 801
Table 52: The Competition through Close Mechanistic Approximation between Cervical Cancer Drugs 801
Table 53: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Lymphocytic Leukemia 803
Table 54: The Competition through Close Mechanistic Approximation between Chronic Lymphocytic Leukemia Drugs 804
Table 55: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelogenous Leukemia 806
Table 56: The Competition through Close Mechanistic Approximation between Chronic Myelogenous Leukemia Drugs 806
Table 57: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Chronic Myelomonocytic Leukemia 807
Table 58: Target Strategy Development Profiles of Antibody Drugs for the Treatment of CNS Cancer 808
Table 59: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Colorectal Cancer 809
Table 60: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 811
Table 61: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Endometrial Cancer 813
Table 62: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Esophageal Cancer 814
Table 63: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ewing’s Sarcoma 815
Table 64 The Competition through Close Mechanistic Approximation between Ewing’s Sarcoma Drugs 815
Table 65: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Fallopian Tube Cancer 816
Table 66: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Cancer (general) 817
Table 67: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 818
Table 68: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stomach Cancer 819
Table 69: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 820
Table 70: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Gastrointestinal Stromal Cancer 821
Table 71: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Genitourinary Cancer 822
Table 72: The Competition through Close Mechanistic Approximation between Genitourinary Cancer Drugs 822
Table 73: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Glioma 823
Table 74: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hairy Cell Leukemia 824
Table 75: The Competition through Close Mechanistic Approximation between Hairy Cell Leukemia Drugs 824
Table 76: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Head and Neck Cancer 825
Table 77: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 826
Table 78: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hematological Cancer (general) 827
Table 79: The Competition through Close Mechanistic Approximation between Hematological Cancer Drugs 827
Table 80: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Hodgkin’s Lymphoma 828
Table 81: The Competition through Close Mechanistic Approximation between Hodgkin’s Lymphoma Drugs 829
Table 82: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leiomyo Sarcoma 830
Table 83: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Leukemia (general) 831
Table 84: The Competition through Close Mechanistic Approximation between Leukemia (general) Drugs 832
Table 85: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Liver Cancer 833
Table 86: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 834
Table 87: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lung Cancer (general) 835
Table 88: The Competition through Close Mechanistic Approximation between Lung Cancer (general) Drugs 836
Table 89: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Lymphoma (general) 837
Table 90: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Malignant ascites 838
Table 91: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Melanoma 839
Table 92: The Competition through Close Mechanistic Approximation between Melanoma Drugs 840
Table 93: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Merkel Cell Carcinoma 842
Table 94: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Mesothelioma 843
Table 95: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myelodysplastic Syndrome 844
Table 96: The Competition through Close Mechanistic Approximation between Myelodysplastic Syndrome Drugs 844
Table 97: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Myeloma 846
Table 98: The Competition through Close Mechanistic Approximation between Myeloma Drugs 847
Table 99: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Nasopharyngeal Cancer 849
Table 100: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroblastoma 850
Table 101: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroectodermal Sarcoma 851
Table 102: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Neuroendocrine Cancer (general) 852
Table 103: Target Strategy Development Profiles of Antibody Drugs for the Treatment of non-Hodgkin’s Lymphoma 853
Table 104: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 855
Table 105: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Non-Small Cell Lung Cancer 857
Table 106: The Competition through Close Mechanistic Approximation between Non-Small Cell Lung Cancer Drugs 859
Table 107: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oesophageal Cancer 860
Table 108: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 862
Table 109: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Oral Cancer 863
Table 110: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Osteo Sarcoma 864
Table 111: The Competition through Close Mechanistic Approximation between Osteo Sarcoma Drugs 864
Table 112: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Ovarian Cancer 865
Table 113: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 867
Table 114: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pancreatic Cancer 868
Table 115: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 870
Table 116: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Peritoneal Cancer 871
Table 117: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 872
Table 118: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Pituitary Adenoma 873
Table 119: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Prostate Cancer 874
Table 120: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 876
Table 121: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Renal Cancer 877
Table 122: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 878
Table 123: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Rhabdomyo Sarcoma 879
Table 124: The Competition through Close Mechanistic Approximation between Rhabdomyo Sarcoma Drugs 879
Table 125: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Sarcoma (general) 880
Table 126: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Appendage Cancer 881
Table 127: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Skin Cancer (general) 882
Table 128: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Small Cell Lung Cancer 883
Table 129: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 884
Table 130: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Soft Tissue Sarcoma 885
Table 131: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Solid Tumor 886
Table 132: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 888
Table 133: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Squamous Cell Cancer 890
Table 134: The Competition through Close Mechanistic Approximation between Squamous Cell Cancer Drugs 890
Table 135: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Synovial Sarcoma 892
Table 136: Target Strategy Development Profiles of Antibody Drugs for the Treatment of T-cell Lymphoma 893
Table 137: The Competition through Close Mechanistic Approximation between T-cell Lymphoma Drugs 893
Table 138: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Testicular Cancer 894
Table 139: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thymoma Cancer 895
Table 140: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Thyroid Cancer 896
Table 141: The Competition through Close Mechanistic Approximation between Thyroid Cancer Drugs 896
Table 142: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Unspecified Cancer Type 898
Table 143: The Competition through Close Mechanistic Approximation between Unspecified Cancer Type Drugs 902
Table 144: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Vaccine adjunct 905
Table 145: Target Strategy Development Profiles of Antibody Drugs for the Treatment of Waldenstrom’s hypergammaglobulinemia 906
Table 146: The Competition through Close Mechanistic Approximation between of Waldenstrom’s hypergammaglobulinemia Drugs 906
Table 147: Competitive Summary by Investigator of Antibody Drug Development in Cancer 908
Table 148: Summary Table of Corporate Changes in the Competitive Landscape of Cacner Antibody Drug Development 913
Table 149: The Worst Ranking and the Highest Populated Level for Each of the 15 Ranking Parameters 916
Table 150: Example of a Competitive Fall-Out Table (Targeting TNFSF11 Modified) 922
Table 151: A&G Pharmaceutical’s Included Antibody Drugs in Oncology and Competitive Fall-Out 926
Table 152: Abbott’s Included Antibody Drugs in Oncology and Competitive Fall-Out 931
Table 153: Abcam’s Included Antibody Drugs in Oncology and Competitive Fall-Out 941
Table 154: Abiogen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 949
Table 155: Ablynx’s Included Antibody Drugs in Oncology and Competitive Fall-Out 957
Table 156: AC Immune’s Included Antibody Drugs in Oncology and Competitive Fall-Out 961
Table 157: Acceleron Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 965
Table 158: Access’ Included Antibody Drugs in Oncology and Competitive Fall-Out 970
Table 159: Actinium Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 976
Table 160: Active Biotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 981
Table 161: Adherex’s Included Antibody Drugs in Oncology and Competitive Fall-Out 985
Table 162: Affibody’s Included Antibody Drugs in Oncology and Competitive Fall-Out 991
Table 163: Affimed Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 999
Table 164: Affitech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1008
Table 165: AGY Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1014
Table 166: Aida Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1019
Table 167: Alder Biopharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1025
Table 168: Alethia Biotherapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1031
Table 169: Alexion’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1035
Table 170: Algeta’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1041
Table 171: ALSP’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1049
Table 172: Altor BioScience’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1054
Table 173: Amgen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1063
Table 174: Amorfix Life Sciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1088
Table 175: Antisoma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1093
Table 176: Aphios’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1099
Table 177: Apricus Biosciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1106
Table 178: Arana Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1112
Table 179: Arca biopharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1116
Table 180: Areva’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1122
Table 181: arGEN-X’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1128
Table 182: Astellas’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1132
Table 183: AstraZeneca’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1140
Table 184: AVEO’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1159
Table 185: Bayer’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1169
Table 186: Berkeley Lab’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1174
Table 187: Biocon’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1178
Table 188: Biogen Idec’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1185
Table 189: BioInvent’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1196
Table 190: Biolex’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1202
Table 191: BioLineRx’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1207
Table 192: Biosceptre’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1211
Table 193: Biotecnol’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1217
Table 194: Biotest’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1223
Table 195: Boehringer Ingelheim’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1227
Table 196: Bristol-Myers Squibb’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1235
Table 197: BTG’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1255
Table 198: Cancer Innovations’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1260
Table 199: Cancer Research Technology’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1267
Table 200: Celldex Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1282
Table 201: Celltrion’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1291
Table 202: Celtic Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1299
Table 203: Center of Molecular Immunology’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1305
Table 204: Centrose’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1312
Table 205: CG Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1317
Table 206: Circadian Technologies’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1321
Table 207: CSL’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1326
Table 208: CuraGen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1330
Table 209: CureTech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1335
Table 210: Customized Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1342
Table 211: CytImmune Sciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1348
Table 212: Daiichi Sankyo’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1353
Table 213: Dendreon’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1360
Table 214: DiaMedica’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1364
Table 215: Dompe’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1369
Table 216: Dr Reddy’s’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1375
Table 217: Dyax’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1381
Table 218: Eisai’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1388
Table 219: Elan’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1394
Table 220: Eli Lilly’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1404
Table 221: Emergent BioSolutions’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1425
Table 222: Ergon Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1429
Table 223: EUSA Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1434
Table 224: Expression Drug Designs’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1438
Table 225: Fabrus’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1446
Table 226: Faron Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1457
Table 227: Favrille’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1463
Table 228: Femta Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1469
Table 229: FibroGen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1473
Table 230: Five Prime Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1477
Table 231: Fusion Antibodies’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1481
Table 232: Galaxy Biotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1485
Table 233: GammaCan’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1490
Table 234: Ganymed Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1495
Table 235: Gene Techno Science’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1499
Table 236: Genencor’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1504
Table 237: Genentech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1511
Table 238: Genmab’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1523
Table 239: Genomic Systems’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1539
Table 240: GenPat77’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1543
Table 241: Gilead Sciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1547
Table 242: GlaxoSmithKline’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1553
Table 243: Gliknik’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1562
Table 244: Glycotope’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1571
Table 245: Green Cross’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1581
Table 246: Hawthorn Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1586
Table 247: Hoffmann-La Roche’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1597
Table 248: Human Genome Sciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1631
Table 249: IDM Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1641
Table 250: ImClone Systems’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1648
Table 251: IMED’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1654
Table 252: Immune Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1658
Table 253: ImmunoCellular Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1662
Table 254: ImmunoGen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1669
Table 255: Immunomedics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1685
Table 256: Immutep’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1708
Table 257: Innate Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1713
Table 258: InNexus Biotechnology’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1722
Table 259: Intracel’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1734
Table 260: ISA Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1740
Table 261: ISU ABXIS’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1746
Table 262: Johnson & Johnson’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1752
Table 263: Kaketsuken’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1759
Table 264: KaloBios’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1763
Table 265: Kirin Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1768
Table 266: Kissei’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1776
Table 267: Kyowa Hakko Kirin’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1782
Table 268: Kyto Biopharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1788
Table 269: LFB Biotechnologies’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1796
Table 270: LG Life Sciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1808
Table 271: MacroGenics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1815
Table 272: MAT Biopharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1822
Table 273: Medarex’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1829
Table 274: MediGene’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1836
Table 275: MedImmune’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1843
Table 276: Menarini’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1848
Table 277: Merck & Co’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1853
Table 278: Merck KGaA’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1861
Table 279: Merrimack’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1872
Table 280: Micromet’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1878
Table 281: Mitsubishi Tanabe Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1882
Table 282: Mycenax’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1886
Table 283: Neovacs’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1891
Table 284: Neuren’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1896
Table 285: NIH’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1901
Table 286: NKT Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1906
Table 287: Non-industrial source’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1912
Table 288: Northwest Biotherapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1919
Table 289: Novartis’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1927
Table 290: OncoMed’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1938
Table 291: OncoTherapy Science’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1943
Table 292: Oncothyreon’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1948
Table 293: Onyvax’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1953
Table 294: Oxford BioMedica’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1958
Table 295: Paladin Labs’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1963
Table 296: Panacea’s Included Antibody Drugs in Oncology and Competitive Fall-Out 1970
Table 297: PanGenetics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1976
Table 298: Patrys’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1981
Table 299: Pepscan Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1988
Table 300: Peregrine Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 1993
Table 301: Perseus Proteomics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2000
Table 302: Pfizer’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2008
Table 303: PharmAbcine’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2029
Table 304: Philogen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2047
Table 305: Pierre Fabre’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2054
Table 306: Prima Biomed’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2062
Table 307: PROBIOMED’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2068
Table 308: ProCell Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2073
Table 309: Prochon Biotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2078
Table 310: Progenics Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2084
Table 311: Ramot’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2088
Table 312: Recepta biopharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2092
Table 313: Receptor BioLogix’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2097
Table 314: Regeneron’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2104
Table 315: Sanofi’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2112
Table 316: SBI Biotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2118
Table 317: Scancell’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2122
Table 318: Seattle Genetics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2128
Table 319: Shanghai CP Guojian’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2140
Table 320: Shenogen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2147
Table 321: Stainwei Biotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2152
Table 322: Sunol Molecular’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2158
Table 323: SuppreMol’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2163
Table 324: Switch Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2167
Table 325: Symphogen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2173
Table 326: Synageva BioPharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2182
Table 327: SynerGene Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2189
Table 328: Tactic Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2193
Table 329: Takeda’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2198
Table 330: Tamir Biotechnology’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2204
Table 331: Targa Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2210
Table 332: TeGenero’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2216
Table 333: Teva’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2222
Table 334: ThromboGenics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2228
Table 335: Titan Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2233
Table 336: Tolerx’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2239
Table 337: Tracon Pharmaceuticals’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2244
Table 338: Transgene’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2249
Table 339: Trillium Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2253
Table 340: Trion Pharma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2259
Table 341: UCB’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2266
Table 342: United Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2271
Table 343: Vaccinex’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2277
Table 344: VasGene Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2284
Table 345: Viragen’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2289
Table 346: Viventia Biotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2294
Table 347: Wakunaga’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2299
Table 348: Wilex’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2304
Table 349: XBiotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2309
Table 350: Xencor’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2318
Table 351: Xerion’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2333
Table 352: Xoma’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2339
Table 353: Y’s Therapeutics’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2344
Table 354: YM BioSciences’ Included Antibody Drugs in Oncology and Competitive Fall-Out 2350
Table 355: Zenotech’s Included Antibody Drugs in Oncology and Competitive Fall-Out 2357

This report includes 205 companies (Incl. Active, Out of Business and M&A) plus their collaborators:
A&G Pharmaceutical
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adherex
Affibody
Affimed Therapeutics
Affitech
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
ALSP
Altor BioScience
Amgen
Amorfix Life Sciences
Antisoma
Aphios
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Areva
arGEN-X
Astellas
AstraZeneca
AVEO
Bayer
Berkeley Lab
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Biosceptre
Biotecnol
Biotest
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Cancer Innovations
Cancer Research Technology
Celldex Therapeutics
Celltrion
Celtic Pharma
Center of Molecular Immunology
Centrose
CG Therapeutics
Circadian Technologies
CSL
CuraGen
CureTech
Customized Therapeutics
CytImmune Sciences
Daiichi Sankyo
Dendreon
DiaMedica
Dompe
Dr Reddy’s
Dyax
Eisai
Elan
Eli Lilly
Emergent BioSolutions
Ergon Pharmaceuticals
EUSA Pharma
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Genmab
Genomic Systems
GenPat77
Gilead Sciences
GlaxoSmithKline
Gliknik
Glycotope
Green Cross
Hawthorn Pharmaceuticals
Hoffmann-La Roche
Human Genome Sciences
IDM Pharma
ImClone Systems
IMED
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Immutep
Innate Pharma
InNexus Biotechnology
Intracel
ISA Pharmaceuticals
ISU ABXIS
Johnson & Johnson
Kaketsuken
KaloBios
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
LFB Biotechnologies
LG Life Sciences
MacroGenics
MAT Biopharma
Medarex
MediGene
MedImmune
Menarini
Merck & Co
Merck KGaA
Merrimack
Micromet
Mitsubishi Tanabe Pharma
Mycenax
Neovacs
Neuren
NIH
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novartis
OncoMed
OncoTherapy Science
Oncothyreon
Onyvax
Oxford BioMedica
Paladin Labs
Panacea
PanGenetics
Patrys
Pepscan Therapeutics
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Philogen
Pierre Fabre
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
Ramot
Recepta biopharma
Receptor BioLogix
Regeneron
Sanofi
SBI Biotech
Scancell
Seattle Genetics
Shanghai CP Guojian
Shenogen
Stainwei Biotech
Sunol Molecular
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Tactic Pharma
Takeda
Tamir Biotechnology
Targa Therapeutics
TeGenero
Teva
ThromboGenics
Titan Pharmaceuticals
Tolerx
Tracon Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
United Therapeutics
Vaccinex
VasGene Therapeutics
Viragen
Viventia Biotech
Wakunaga
Wilex
XBiotech
Xencor
Xerion
Xoma
YM BioSciences
Y’s Therapeutics
Zenotech
This report includes 572 cancer antibody drugs. From Ceased to Marketed. Some examples are:
131I-tositumomab
abagovomab
adecatumumab
aflibercept
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
AV-299
belimumab
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
brentuximab vedotin
BT-062
carlumab
catumaxomab
CDX-1307
CDX-1401
cetuximab
cixutumumab
CMAB302
CMAB304
conatumumab
CT-011
dalotuzumab
daratumumab
denosumab
elotuzumab
EMD-273063
EMD525797
epratuzumab
epratuzumab-Y90
ertumaxomab
farletuzumab
figitumumab
fresolimumab
galiximab
ganitumab
gemtuzumab ozogamicin
girentuximab
glembatumumab vedotin
GS-6634
I-131-labetuzumab
ibritumomab tiuxetan
icrucumab
inotuzumab ozogamicin
intetumumab
IPH-2102
ipilimumab
iratumumab
L19-TNFalpha
lintuzumab
LIP-131I
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
MCS-110
MEDI-551
MEDI-573
milatuzumab
milatuzumab-doxorubicin
MM-111
MM-121
mogamulizumab
MOR202
MOR208
MORAb-004
moxetumomab pasudotox
naptumomab estafenatox
natalizumab
necitumumab
nimotuzumab
obinutuzumab
ofatumumab
olaratumab
onartuzumab
Onyvax-105
oregovomab
panitumumab
PAT-SC1
pertuzumab
PF-4856884
ramucirumab
Reditux
RG-7160
rilotumumab
rituximab
robatumumab
romiplostim
samalizumab
SAR-3419
siltuximab
sotatercept
Sym-004
Tenarad
tigatuzumab
tocilizumab
TRC-105
tremelimumab
TRU-016
tucotuzumab celmoleukin
U3-1287
Ublituximab
veltuzumab
volociximab
yttrium Y 90 clivatuzumab tetraxetan
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Cancer Antibodies: Drug Target Atlas and Competitive Outlook.
    To find out more about Cancer Antibodies: Drug Target Atlas and Competitive Outlook, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Cancer Antibodies: Drug Target Atlas and Competitive Outlook is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Cancer Highlights' category:


Leukemia - A Therapeutic & Competitive Insight
In the report "Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. Learn More


The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others
This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Leukemia, Lung Cancer and Antibodies
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lung Cancer and by the compound strategy of Antibodies. Learn More


Triple Analysis: Lung Cancer, Lymphoma and Prostate Cancer
This triple analysis focuses on cancer drug development strategies in Lung Cancer, Lymphoma and Prostate Cancer. Learn More

Other selected research from the 'Biologicals' category:


Nucleic Acid Therapies in Oncology Drug Pipeline Update
BioSeeker Group have identified 308 companies plus partners who are today developing 381 nucleic acid therapy drugs in 775 developmental projects in cancer across 251 different targets. In addition, there are 9 suspended drugs and another 211 drugs where development has been ceased. Learn More


RNA (miRNA, RNAi & siRNA) Therapy in Oncology Drug Pipeline Update
BioSeeker Group have identified 103 companies plus partners who are today developing 131 RNA (miRNA, RNAi & siRNA) drugs in 198 developmental projects in cancer across 103 different targets. In addition, there are 2 suspended drugs and another 39 drugs where development has been ceased. Learn More